Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected
This article was originally published in The Pink Sheet Daily
FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.
You may also be interested in...
Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.
New drugs for psoriasis and psoriatic arthritis have been in the spotlight recently, with new approvals and full pivotal data releases at the recent American Academy of Dermatology meeting. But how the drugs can make inroads in a safety- and cost-cautious market that will soon feature biosimilars remains to be seen.
With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.